Product Pipeline

Product Pipeline
Proprietary Programs
Betrixaban
PRT064445: FXa Inhibitor Antidote
PRT062070: Dual Syk-JAK Inhibitor
JAK3 Program
Partnered Programs
PRT062607: Syk-Specific Inhibitor
Elinogrel
Clinical Trials
Publications

Clinical Trials

EXPLORE-Xa, a 508-patient Phase 2 trial of the safety and tolerability of betrixaban compared to warfarin for stroke prevention in atrial fibrillation (SPAF) has been completed. Phase 3 trials of betrixaban are planned. Please check back for more information.

To learn more about clinical trials, please visit www.clinicaltrials.gov, a service of the U.S. National Institutes of Health.